Scancell Holdings Plc Licenses Vaccitech technology to advance Modi-2 (4381F)
November 07 2022 - 01:00AM
UK Regulatory
TIDMSCLP
RNS Number : 4381F
Scancell Holdings Plc
07 November 2022
7 November 2022
Scancell Holdings plc
("Scancell" or the "Company")
Scancell in-licenses Vaccitech technology to advance Modi-2
towards the clinic
SNAPvax(TM) technology to provide optimal method of formulation
for Modi-2
Company expects to initiate a Phase 1 clinical study with Modi-2
in 2024
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies, today announces it has in-licensed the SNAPvax(TM)
technology from Vaccitech plc, a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapies and vaccines. This agreement will allow Scancell to
formulate and manufacture Modi-2, with the aim of initiating a
Phase 1 clinical study in cancer patients in 2024.
Modi-2 is the second product from the Company's Moditope(R)
platform, which leverages the immune system to target a unique
class of post-translational modifications (PTMs) upregulated by
many cancers. The SNAPvax(TM) technology enables peptides to
self-assemble with TLR-7/8a, a powerful adjuvant, to promote strong
T cell responses and is proven to successfully overcome formulation
issues associated with immunogenic peptide antigens, which are
often highly hydrophobic and prone to manufacturing challenges with
conventional formulations(1) . Modi-2 will use SNAPvax(TM) to
codeliver homocitrullinated peptide antigens and TLR-7/8a adjuvants
in self-assembling nanoparticles designed to prime tumour killing T
cells. The Company expects that the combination of Scancell's
Modi-2 with a highly effective platform for inducing T cells
(Vaccitech's SNAPvax(TM) technology) will lead to a potentially
superior therapeutic vaccine candidate.
Scancell's Moditope(R) platform also consists of Modi-1, which
is currently in a Phase 1 clinical study. Modi-1 targets
citrullinated proteins, in contrast to Modi-2 which targets
homocitrullinated proteins. Homocitrullination is a process that
occurs by a different mechanism compared to citrullination and is
therefore applicable to a distinct set of highly immune suppressed
tumours. Scancell will leverage its deep understanding of T cell
immunology and cancer immunotherapy together with its strong
development capabilities to bring Modi-2 to clinical validation,
adding value to the entire Moditope(R) platform.
Prof Lindy Durrant, Chief Executive Officer, Scancell ,
commented: "We are pleased to partner with Vaccitech to take the
second candidate from our Moditope(R) platform through GMP and
subsequent clinical development. With its elegant and effective
solution, the SNAPvax(TM) technology provides an excellent method
for formulation of the Modi-2 vaccine. Combining this technology
with our expertise will allow us to develop a rapid manufacturing
process for Modi-2, with the hope that we can bring it into a Phase
1 clinical study during 2024."
Dr Geoffrey Lynn, Senior Vice President of Synthetic Platforms
at Vaccitech commented : "We are delighted that Scancell has
selected our SNAPvax(TM)technology for the development of their
Modi-2 product. SNAPvax(TM) was developed to overcome the
challenges of formulating and delivering PTMs and ensure consistent
formulations of any peptide antigens, for reliable T cell priming.
Our team is therefore keen to support the development of this
promising product with the hope that it will address immediate
needs of cancer patients and more broadly highlight the promise of
targeting PTMs."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
(1) - Lynn, G.M., Sedlik, C., Baharom, F. et al.
Peptide-TLR-7/8a conjugate vaccines chemically programmed for
nanoparticle self-assembly enhance CD8 T-cell immunity to tumor
antigens. Nature Biotechnology 38, 320-332 (2020).
https://doi.org/10.1038/s41587-019-0390-x
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr John Chiplin, Executive Chairman
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated
Advisor and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/ Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Rob Winder/Alex Davis
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope (R) and
ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody
(R) ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab(R) ) or enhances
the potency of antibodies and their ability to directly kill tumour
cells (AvidiMab (R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
About Vaccitech
Vaccitech is a clinical-stage biopharmaceutical company engaged
in the discovery and development primarily of novel immunotherapies
for the treatment of chronic infectious diseases, cancer,
autoimmunity and diseases where the T cell arm of the immune system
is believed to play an important role. The company's proprietary
platforms include modified simian adenoviral vectors (ChAdOx1 and
ChAdOx2), other viral vectors including the well-validated Modified
Vaccinia Ankara (MVA) and synthetic nano-particle technologies
(SNAPvax(TM) and Syntholytic(TM)). The combination of different
technologies in a mix and match approach (heterologous prime-boost)
consistently generates significantly higher magnitudes of T cells
compared with other technologies and approaches. The company has a
broad pipeline of both clinical and preclinical stage therapeutic
programs to treat solid tumors, chronic viral infections, as well
as a few prophylactic viral vaccine programs. Vaccitech co-invented
a COVID-19 vaccine with the University of Oxford, now approved for
use in many territories and exclusively licensed worldwide to
AstraZeneca through Oxford University Innovation, or OUI. Vaccitech
is entitled to receive a share of all milestones and royalty income
received by OUI from AstraZeneca.
For further information about Vaccitech, please visit:
https://vaccitech.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBIBRTMTTMBFT
(END) Dow Jones Newswires
November 07, 2022 02:00 ET (07:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2023 to Mar 2024